Quintiles expands operations in China

US-headquartered biopharma services provider Quintiles yesterday announced agreements to establish a regional headquarters for China in Shanghai and to significantly expand lab testing capabilities in China, underscoring the growing importance of this country to the global biopharmaceutical industry.

“With its burgeoning economy and growing health care needs for its 1.3 billion citizens, China exemplifies the opportunities and challenges of the New Health,” said Quintiles executive chairman Dennis Gillings, adding: “By broadening our investment and infrastructure here, Quintiles is ready to partner with our biopharma customers as they look to realize China’s potential.”

Under a joint venture agreement, Quintiles will engage the Shanghai Clinical Research Centre (SCRC) to provide lab testing services to local customers.